Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States
China's NMPA has approved etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia in adults, marking the first regulatory approval of the drug outside the United States. The approval triggers a $2.0 million milestone payment to Milestone from Everest Medicines, its exclusive Greater China licensee, which will lead commercialization in a market with an estimated 3-6 million diagnosed PSVT patients. Milestone remains eligible for up to $98.0 million in additional milestones plus tiered royalties of up to 18% on future China sales.
Key figures
- Drug Name
- etripamil nasal spray (CARDAMYST)
- Phase Of Trial
- Phase 3
- P value
- 0.0005
- Royalty max
- 18%
- Hazard ratio
- 3.002
- Hazard ratio ci
- 95% CI: 1.578, 5.711
- Psvt patients us
- 2 million
- Psvt patients china
- 3-6 million
- Milestone payment usd
- 2000000
- Potential milestones usd
- 98000000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.